Slade M, Fakhri B, Savani B N, Romee R
Washington University School of Medicine, St. Louis, MO, USA.
Vanderbilt University School of Medicine, Nashville, TN, USA.
Bone Marrow Transplant. 2017 Jan;52(1):1-6. doi: 10.1038/bmt.2016.190. Epub 2016 Jul 25.
In recent years, the use of haploidentical donors for hematopoietic cell transplantation has expanded rapidly. Approximately 50% of patients requiring hematopoietic cell transplant lack a traditional donor. The use of HLA haploidentical-related donors is attractive due to nearly universal availability of this graft source. We summarize the current and future need for haploidentical donors and detail the rise of post-transplant cyclophosphamide as the dominant haploidentical approach. Further, we examine ongoing controversies in the field of haploidentical transplant, including conditioning regimens and graft source. Finally, we review the evidence available from preliminary comparative studies and discuss future direction of research.
近年来，单倍体相合供者用于造血细胞移植的情况迅速增加。大约50%需要造血细胞移植的患者缺乏传统供者。由于这种移植物来源几乎普遍可得，HLA单倍体相合相关供者的使用很有吸引力。我们总结了当前及未来对单倍体相合供者的需求，并详细阐述了移植后环磷酰胺作为主要单倍体相合方法的兴起。此外，我们审视了单倍体相合移植领域中存在的争议，包括预处理方案和移植物来源。最后，我们回顾了初步比较研究中的现有证据，并讨论了未来的研究方向。
